Adam J. Bass

Adam J. Bass

Auto-generated profile, based on publicly available information

Adam J. Bass

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ADAustin M Dulak
Austin M Dulak
PSPetar Stojanov
Petar Stojanov
SPShouyong Peng
Shouyong Peng
MLMichael S Lawrence
Michael S Lawrence
CFCameron Fox
Cameron Fox
ABAdam J Bass
Adam J Bass
Adam Bass, Gad Getz and colleagues report whole-exome sequencing of 149 esophageal adenocarcinomas (EACs) and whole-genome sequencing of 15 EACs. They identify a mutational signature defined by a high prevalence of A>C transversions, as well as 26 genes mutated at high frequency in EACs. The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of ∼15%, the identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole-exome sequencing of 149 EAC tumor-normal pairs, 15 of which have also been subjected to whole-genome sequencing. We identify a mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides. Statistical analysis of exome data identified 26 significantly mutated genes. Of these genes, five (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA) have previously been implicated in EAC. The new significantly mutated genes include chromatin-modifying factors and candidate contributors SPG20, TLR4, ELMO1 and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 identifies increased cellular invasion. Therefore, we suggest the potential activation of the RAC1 pathway as a contributor to EAC tumorigenesis.

1 April 2018 in Cancer Cell
Verified
Journal Article
Open access
YLYang Liu
Yang Liu
NSNilay S. Sethi
Nilay S. Sethi
THToshinori Hinoue
Toshinori Hinoue
BSBarbara G. Schneider
Barbara G. Schneider
ACAndrew D. Cherniack
Andrew D. Cherniack
ABAdam J. Bass
Adam J. Bass
We analyzed 921 adenocarcinomas of the esophagus, stomach, colon, and rectum to examine shared and distinguishing molecular characteristics of gastrointestinal tract adenocarcinomas (GIACs). Hypermutated tumors were distinct regardless of cancer type and comprised those enriched for insertions/deletions, representing microsatellite instability cases with epigenetic silencing of MLH1 in the context of CpG island methylator phenotype, plus tumors with elevated single-nucleotide variants associated with mutations in POLE. Tumors with chromosomal instability were diverse, with gastroesophageal adenocarcinomas harboring fragmented genomes associated with genomic doubling and distinct mutational signatures. We identified a group of tumors in the colon and rectum lacking hypermutation and aneuploidy termed genome stable and enriched in DNA hypermethylation and mutations in KRAS, SOX9, and PCBP1.

10 April 2019 in Nature
Verified
Journal Article
Closed access
PDF file
ECEdmond M. Chan
Edmond M. Chan
TSTsukasa Shibue
Tsukasa Shibue
JMJames M. McFarland
James M. McFarland
BGBenjamin Gaeta
Benjamin Gaeta
MGMahmoud Ghandi
Mahmoud Ghandi
ABAdam J. Bass
Adam J. Bass

20 July 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MSMatthew D Stachler
Matthew D Stachler
ATAmaro Taylor-Weiner
Amaro Taylor-Weiner
SPShouyong Peng
Shouyong Peng
AMAaron McKenna
Aaron McKenna
AAAgoston T Agoston
Agoston T Agoston
ABAdam J Bass
Adam J Bass
Adam Bass, Gad Getz, Scott Carter and colleagues report the whole-exome sequences of 25 pairs of esophageal adenocarcinoma and Barrett's esophagus. They identify two pathways by which Barrett's esophagus can develop into esophageal adenocarcinoma. Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy. Here we present whole-exome sequencing from 25 pairs of EAC and Barrett's esophagus and from 5 patients whose Barrett's esophagus and tumor were extensively sampled. Our analysis showed that oncogene amplification typically occurred as a late event and that TP53 mutations often occurred early in Barrett's esophagus progression, including in non-dysplastic epithelium. Reanalysis of additional EAC exome data showed that the majority (62.5%) of EACs emerged following genome doubling and that tumors with genomic doubling had different patterns of genomic alterations, with more frequent oncogenic amplification and less frequent inactivation of tumor suppressors, including CDKN2A. These data suggest that many EACs emerge not through the gradual accumulation of tumor-suppressor alterations but rather through a more direct path whereby a TP53-mutant cell undergoes genome doubling, followed by the acquisition of oncogenic amplifications.

27 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
YCYael Cohen-Sharir
Yael Cohen-Sharir
JMJames M. McFarland
James M. McFarland
MAMai Abdusamad
Mai Abdusamad
CMCarolyn Marquis
Carolyn Marquis
SBSara V. Bernhard
Sara V. Bernhard
UBUri Ben-David
Uri Ben-David

1 January 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EPEirini Pectasides
Eirini Pectasides
MSMatthew D. Stachler
Matthew D. Stachler
SDSarah Derks
Sarah Derks
YLYang Liu
Yang Liu
SMSteven Maron
Steven Maron
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies is that genomic profiling results could commonly differ between the primary and metastatic tumors. To evaluate genomic heterogeneity, we sequenced paired primary GEA and synchronous metastatic lesions across multiple cohorts, finding extensive differences in genomic alterations, including discrepancies in potentially clinically relevant alterations. Multiregion sequencing showed significant discrepancy within the primary tumor (PT) and between the PT and disseminated disease, with oncogene amplification profiles commonly discordant. In addition, a pilot analysis of cell-free DNA (cfDNA) sequencing demonstrated the feasibility of detecting genomic amplifications not detected in PT sampling. Lastly, we profiled paired primary tumors, metastatic tumors, and cfDNA from patients enrolled in the personalized antibodies for GEA (PANGEA) trial of targeted therapies in GEA and found that genomic biomarkers were recurrently discrepant between the PT and untreated metastases. Divergent primary and metastatic tissue profiling led to treatment reassignment in 32% (9/28) of patients. In discordant primary and metastatic lesions, we found 87.5% concordance for targetable alterations in metastatic tissue and cfDNA, suggesting the potential for cfDNA profiling to enhance selection of therapy. Significance: We demonstrate frequent baseline heterogeneity in targetable genomic alterations in GEA, indicating that current tissue sampling practices for biomarker testing do not effectively guide precision medicine in this disease and that routine profiling of metastatic lesions and/or cfDNA should be systematically evaluated. Cancer Discov; 8(1); 37–48. ©2017 AACR. See related commentary by Sundar and Tan, p. 14. See related article by Janjigian et al., p. 49. This article is highlighted in the In This Issue feature, p. 1